Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

GLAUKOS CORPORATION

(GKOS)
  Report
Delayed Nyse  -  04:00:01 2023-01-27 pm EST
48.04 USD   -0.29%
01/11Glaukos Announces Positive Results for iDose TR Exchange Trial Highlighting Favorable Safety and Tolerability
AQ
01/10Transcript : Glaukos Corporation Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-10-2023 05:15 PM
CI
01/10Glaukos Says iDose TR Exchange Trial Shows 'Favorable' Safety, Tolerability; Shares Up After Hours
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Glaukos Announces Participation in the Stephens Annual Investment Conference

11/07/2022 | 07:30am EST

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Stephens Annual Investment Conference on Wednesday, November 16, 2022, at 2:00 p.m. CT in Nashville, TN.

A live and archived webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and continues to develop a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases.


ę Business Wire 2022
All news about GLAUKOS CORPORATION
01/11Glaukos Announces Positive Results for iDose TR Exchange Trial Highlighting Favorable S..
AQ
01/10Transcript : Glaukos Corporation Presents at 41st Annual J.P. Morgan Healthca..
CI
01/10Glaukos Says iDose TR Exchange Trial Shows 'Favorable' Safety, Tolerability; Shares Up ..
MT
01/10Glaukos : Investor Presentation January 2023
PU
01/10Glaukos Corp : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
01/10Glaukos Announces Positive Clinical Updates for Several Corneal Health Pipeline Program..
BU
01/10Glaukos Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable ..
BU
01/10Glaukos Corporation Announces Positive Results for iDose TR Exchange Trial, Highlightin..
CI
01/10Glaukos Corporation Announces Positive Clinical Updates for Several Corneal Health Pipe..
CI
2022Glaukos Announces Participation in the J.P. Morgan Healthcare Conference 2023
AQ
More news
Analyst Recommendations on GLAUKOS CORPORATION
More recommendations
Financials (USD)
Sales 2022 280 M - -
Net income 2022 -90,2 M - -
Net Debt 2022 - - -
P/E ratio 2022 -24,4x
Yield 2022 -
Capitalization 2 290 M 2 290 M -
Capi. / Sales 2022 8,19x
Capi. / Sales 2023 7,52x
Nbr of Employees 727
Free-Float 96,0%
Chart GLAUKOS CORPORATION
Duration : Period :
Glaukos Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAUKOS CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 48,04 $
Average target price 56,70 $
Spread / Average Target 18,0%
EPS Revisions
Managers and Directors
Thomas William Burns Chairman & Chief Executive Officer
Joseph E. Gilliam President & Chief Operating Officer
Alex Thurman Chief Financial Officer & Senior Vice President
Jay L. Katz Chief Medical Officer
David F. Hoffmeister Independent Director
Sector and Competitors